androgen ablation

androgen ablation

The therapeutic reduction of circulating androgens (testosterone and 5alpha-dihydrotestosterone) by either orchiectomy or by an luteinizing hormone-releasing hormone (LHRH) agonist. Androgen ablation is commonly used in metastatic prostate cancer and results in disease attenuation (12–18 months) in up to 80% of patients. Androgen ablation can be augmented by flutamide, an androgen receptor antagonist that blocks the effect of androgens produced by the adrenal gland.
References in periodicals archive ?
To help facilitate a comparison with the previously reported ECOG 3805: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) study, which stratified patients by high or low tumour volume, the investigators of the GETUG-AFU 15 study retrospectively assessed tumour volume and performed sub-analyses on these separate populations.
6) Androgen ablation therapy is frequently used in prostate cancer management because it has been shown that a significant reduction in serum testosterone levels results in regression of advanced prostate cancer.
For more advanced cancers that have either recurred or metastasized, the gold standard treatment is androgen ablation therapy (2).
Selectively blocking the hormone will be key if we hope to prevent the side effects associated with androgen ablation in males," he said.
We (5) have recently reported a direct analysis of the expression of the TMPRSS2:ERG fusion gene in surgical samples from a total of 84 patients, 24 of whom had received presurgery androgen ablation therapy.
For decades, androgen ablation has remained the frontline treatment for CaP that is no longer organ-confined and thus deemed surgically inoperable.
Adjuvant radiotherapy also increased biochemical control, avoided the need for androgen ablation, decreased detectable local failures, and decreased metastatic disease.
Early-stage prostate cancer typically requires androgen for growth and thus responds to androgen ablation (Feldman and Feldman 2001).
of Rochester, New York)-- the first to clone the androgen receptor--introduces 17 chapters in which specialists from US and Japanese institutions discuss current therapies including: hormonal therapy, immunotherapy, chemotherapy, radiation therapy, gene therapy, and androgen ablation therapies.
Consequently, median survival is less than 12 months after failure of initial androgen ablation for metastatic disease.
Patients at high risk for recurrence should be considered for either androgen ablation or a combination of radiation therapy and androgen ablation;
Although radical prostatectomy, radiation, and androgen ablation are effective therapies for androgen-dependent prostate cancer, metastatic castration-resistant prostate cancer still remains a major problem with high mortality.